Digital Transformation for Biotechnology and Life Sciences
Biotechnology companies move from discovery to production under tight control. Routeget connects research, materials, batch and quality data so scientific progress converts into reliable supply.
30+
clients served
$15M+
Savings Delivered
15+ yrs
Serving the Sector
20+
Projects Delivered
Biotechnology and Life Sciences: where the market stands today
A fact base for planning. All figures below are third-party research estimates, not Routeget data, and they differ by how each firm defines the market.
Innovation and capital intensive
Genomics, cell and gene therapies and AI-assisted discovery drive investment and demand for specialised manufacturing.
About US$1.55 to 1.95 trillion
Grand View Research and BioSpace size the global biotechnology market in this range for 2024.
About 12% to 15.9% CAGR
Precedence Research and others project growth clustered around 13.5% to 14%.
Tech transfer and supply reliability
Complete material and batch records speed transfer to manufacturing partners and support regulatory filings.
Sources: Grand View Research; BioSpace; Precedence Research; Dataintelo. Figures vary by publisher and definition; verify before external citation. Estimates retrieved October 2026 and subject to each publisher’s definitions; verify against the publisher before citing externally.
End-to-end digital transformation
Strategy, platform selection, integration and data work delivered as one programme.
Regulated-industry data models
Batch, lot, specification and change records designed for GxP-style environments.
Compliance and audit readiness
Electronic records, approvals and traceability built into daily workflows.
Laboratory and plant integration
Connections between laboratory systems, production, warehouse and finance.
Four pressures that shape bio tech & life science operations
These are the recurring problems we see when process development, scale-up, production and quality operations run on disconnected systems.
Scale-up uncertainty
Process data from the lab to production is scattered across notebooks and files.
Sensitive materials
Cold-chain and short-expiry materials are managed on manual logs.
Partner manufacturing
Contract partners hold records the sponsor cannot see in time.
Capabilities built for process development, scale-up, production and quality operations
Pick the area closest to your priority. Each can be delivered on its own or as part of a wider programme.
Keep controlled records for biotechnology products.
- Formula, specification and master-record management
- Batch records with in-process checks
- Change control and deviation workflows
- Lot genealogy from ingredient to customer
Make audits routine rather than a project.
- Electronic approvals and audit trails
- Supplier qualification and material release
- Complaint, recall and CAPA workflows
- Document and training control
Connect the lab to the plant.
- Sample, test and result tracking by lot
- Stability and retention sample management
- Equipment calibration and maintenance records
- Yield and cost by batch
Plan, ship and sell with control.
- Controlled-temperature and expiry-aware stock
- Serialisation and customer shipment records
- Tender, contract and price management
- Margin by product, market and channel
Two scenarios where connected data changes the day-to-day
These are illustrative scenarios that describe the business objective. They are not customer case studies.
Transferring a process to a partner
Process parameters, materials and results assemble into a transfer package.
Business objective: shorten tech transfer.
Controlling sensitive inventory
Expiry and temperature data trigger alerts and priority use of materials.
Business objective: reduce losses of costly materials.
How we approach delivery and evidence outcomes
We do not publish unverified customer figures on industry pages. This is how we make outcomes measurable in an engagement.
Baseline first
We agree the starting measures with you before design, such as batch success rate, tech-transfer time and inventory expiry loss.
Delivery in stages
Releases are phased by site and process, so each stage is tested against real operations before the next.
Measured against your targets
Dashboards report the baseline measures from go-live, so benefit is judged on your data.
Examples of Routeget engagements can be discussed in a discovery call, subject to client approval for each reference.
Why Routeget for bio tech & life science
We bring a delivery approach built around the realities of long development cycles, sensitive materials and exacting records.
Programme and material depth
We link programme, material and batch data so scale-up evidence is complete and transferable.
Integrated, not stitched together
Laboratory, production, quality, warehouse and finance share one data model, so operational and financial records reconcile.
Phased, low-disruption rollout
We plan releases around funding rounds, trial milestones and regulatory reviews to protect service levels.
Data you can act on
Analytics are designed with your operations team, so measures reflect how your plants actually run.
Related reading from the Routeget team
Perspectives on the supply chain, data and integration topics behind this industry.
Why Automating our Supply Chain is Crucial to your Business Success
Why supply chain automation matters for service levels, cost and resilience.
The Evolving Landscape of Data Modernization Engineering
Trends in data modernization engineering and how they affect enterprise platforms.
AI attracts a new generation while assisting Argentine small producers and winemakers in competing
How AI is helping small producers compete in demanding markets.
Explore adjacent industry practices
Plan your bio tech & life science digital foundation with Routeget
Book a 30-minute discovery to walk through your laboratories, pilot plants, partners and manufacturing sites and your priorities with a Routeget industry specialist.
Your details are used only to respond to this enquiry. See our Privacy Policy.
Bio Tech & Life Science: questions buyers ask us
How do you engage with a bio tech & life science business?
We usually start with a short discovery and a process review of one programme and its development batches. From there we propose a phased scope, which can be fixed-scope for defined releases or a time-and-materials team for ongoing improvement.
Can you support research-to-production data flow?
Development, pilot and commercial batches share a data model so history carries forward.
Do you manage outsourced manufacturing?
Partner stock, orders and batch records are visible alongside your own.
Who owns the data and the configuration?
You do. The solution runs in your own environment, and configuration, data models and reports are documented and handed over so your team can maintain them.
How do you approach pricing and timelines?
Pricing and timing follow scope, including the number of programmes, sites and outsourced partners. We share an estimate after discovery, with assumptions and exclusions stated, and we confirm timelines only after reviewing your landscape.